Anti-aggregant activity of new xanthine derivative under conditions of hyper aggregation of platelets in vitro

Abstract

Aim. To study the anti-aggregant activity and the effectiveness of firstly synthesized cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid as a potential antiplatelet agent under in vitro conditions.
 Methods. Experimental work was carried out on the blood of healthy donors and 74 male patients diagnosed with thrombosis of various localization. Thromboelastography of citrate blood samples was performed in the presence of the test substances on the device TEG 5000. The analysis determined the overall trend of coagulation, functional activity of platelets and fibrinogen, fibrinolytic activity and physico-mechanical properties of clots formed. ADP-, collagen-, and epinephrine-induced platelet aggregations were registered. Agregatogramm analysis was performed using software AGGR. We evaluated the general nature of the aggregation, the maximum aggregate, maximum aggregation rate, the average size of platelet aggregates.
 Results. Cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid in in vitro conditions showed anti-aggregant activity greater than the reference substance, and effectively suppress hypercoagulation caused by an excess of thrombin and tissue factor.
 Conclusion. The results of the study make it possible to establish in a potentially high ex vivo therapeutic effect of a cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid under conditions involving platelet hyperaggregation.